Evotec SE Virtual Annual General Meeting 2021; Approves All Proposed Agenda Items
Evotec SE successfully held its virtual Annual General Meeting 2021, with shareholders approving all management proposals, including financial strategies and appointments. Key highlights include the election of Dr. Constanze Ulmer-Eilfort to the Supervisory Board, replacing Prof. Dr. Wolfgang Plischke, who resigned. The meeting also authorized a new capital plan, setting Authorized Capital 2021 at 20% of share capital. 65.17% of registered capital participated in the vote, indicating strong shareholder engagement and support for the company's strategic direction.
- All proposals at the Annual General Meeting approved by shareholders.
- Appointment of Dr. Constanze Ulmer-Eilfort strengthens the Supervisory Board with expertise in intellectual property.
- New Authorized Capital 2021 allows for strategic financial maneuvers.
- Resignation of long-standing Chairman Prof. Dr. Wolfgang Plischke may lead to transitional challenges in leadership.
- ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY
- DR CONSTANZE ULMER-EILFORT ELECTED AS NEW MEMBER OF THE SUPERVISORY BOARD
- PROF. DR WOLFGANG PLISCHKE RESIGNS FROM HIS OFFICE AS CHAIRMAN OF THE SUPERVISORY BOARD
HAMBURG, GERMANY / ACCESSWIRE / June 15, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's virtual Annual General Meeting 2021 with the required majority. Due to the COVID-19 pandemic, this year's Annual General Meeting again was held as a purely virtual event.
First, CEO Dr. Werner Lanthaler and CFO Enno Spillner presented Evotec SE's new strategic direction - the "Action Plan 2025" - as well as the business development and highlights of the fiscal year 2020.
All actions of the Management Board and the Supervisory Board were approved by the Annual General Meeting 2021 for the fiscal year 2020. Furthermore, the shareholders confirmed the appointment of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, Hamburg, as auditors for the fiscal year 2021.
The Annual General Meeting also elected a new member of the Supervisory Board: Effective immediately, Dr Constanze Ulmer-Eilfort will become a new member of the Supervisory Board of Evotec SE. Dr Constanze Ulmer-Eilfort has been a partner in the Munich office of the law firm Baker McKenzie for more than 20 years and has been a member of the Global Executive Committee for several years. She has long-term and extensive experience in advising high-tech, pharmaceutical and media companies on the protection and marketing of their intellectual property rights and on a wide range of agreements, including cooperation and licensing agreements, R&D agreements and agreements with academic institutions.
The long-standing Chairman of the Supervisory Board, Prof. Dr Wolfgang Plischke, resigned from his office for personal reasons. As confirmed by the Supervisory Board today following the Annual General Meeting, the former vice chairperson Prof. Dr Iris Löw-Friedrich will initially become the new Chairwoman of the Supervisory Board.
"I would like to express my sincere thanks, also on behalf of my colleagues on the Evotec Management Board, to our long-standing Supervisory Board Chairman Prof. Dr Wolfgang Plischke for the great cooperation over the last seven years. We always appreciated his very qualified advice and constructive feedback. At the same time, I would like to warmly welcome Dr Ulmer-Eilfort to the Supervisory Board of Evotec SE. I look forward to working with her," said Dr Werner Lanthaler, Chief Executive Officer of Evotec.
Prof. Dr Wolfgang Plischke, former Chairman of the Supervisory Board of Evotec SE, said: "Due to personal reasons I have made the decision to resign from my office in the Supervisory Board of Evotec SE, effective as of the end of the ordinary Annual General Meeting 2021. Over the past seven years, I have thoroughly enjoyed working together with my colleagues in the Supervisory Board and also the close and without exception constructive collaboration with Evotec's entire Management Board. I am particularly glad to be initially succeeded in my office by Prof. Dr Iris Löw-Friedrich, a colleague who has served in Evotec's Supervisory Board for as long as I have and who knows the Company extremely well. Additionally, with the appointment of Dr Constanze Ulmer-Eilfort, Evotec's Supervisory Board gains a proven expert in the protection of intellectual property - which is an eminently important area for the Company. I look forward to following Evotec's continued successful development with great interest in the future".
Likewise, the shareholders approved with the required majority the cancellation of the Authorised Capital 2017 and the creation of a new authorised capital (Authorised Capital 2021) in the amount of
The new remuneration systems of the Management Board and the Supervisory Board were also approved.
In total,
More information on the Company's Annual General Meeting including the voting results on all agenda items can be found on the Company's website at https://www.evotec.com/en/invest/annual-general-meeting.
ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com
SOURCE: Evotec AG
View source version on accesswire.com:
https://www.accesswire.com/651805/Evotec-SE-Virtual-Annual-General-Meeting-2021-Approves-All-Proposed-Agenda-Items
FAQ
What were the outcomes of Evotec's Annual General Meeting on June 15, 2021?
Who was elected to the Supervisory Board of Evotec SE in 2021?
What is the significance of the new Authorized Capital 2021 for Evotec?
What percentage of shareholders participated in Evotec's virtual Annual General Meeting?
